Why has the EU been so slow to roll out a Covid vaccination programme?

Europe was not prepared for the pandemic, but it must now learn lessons and use all its financial and political resources.

By: Date: January 28, 2021 Topic: Macroeconomic policy

This opinion piece was originally published on El País, Süddeutsche Zeitung and the Guardian.

El País logo

For the European Union, the rapid rollout of Covid-19 vaccines is critical to save lives and prevent health services from being stretched beyond their limits, not to mention minimising the massive economic damage from lockdowns. Unfortunately, however, though vaccinations are under way, a rapid near-term increase in infections is likely as the British variant of the virus spreads across the continent.

The problem for the EU is compounded because its vaccination programme already trails Israel, the UK and the US. The best performing EU country, Denmark, has vaccinated a meagre 3.6 people per 100, compared with 45 in Israel and more than 10 in the UK. Germany and France are even further behind. More worryingly, there are no signs that the vaccination rate in the EU is accelerating, unlike in the UK and US, where daily vaccination rates have increased substantially in the past few weeks.

The European commission and European leaders have recognised the need for rapid action. The commission intends to have 80% of those over 80 and the same percentage of health workers in the EU vaccinated by March, with 70% of the adult population vaccinated by the summer. Acceleration of the vaccination campaign is now the EU’s number one priority.

Why is the EU lagging behind? The central issue is not so much the organisational issues, but the lack of vaccines. Even Denmark has had to slow down its campaign significantly because of short supply. Many countries now report fully operational vaccine centres but insufficient vaccines. As always in such complex issues, there is no single answer as to why this is happening.

Part of the explanation is that the EU ordered too few vaccines too late. It was slow to order the BioNTech-Pfizer vaccine, even when it became the frontrunner and its efficacy had been documented. Member states hesitated to ask the EU to order more because of the novelty of the technological approach, and the commission leadership did not push hard enough for additional purchases.

Purchases were slowed down further as the EU insisted that liability in case of negative side-effects on health remains with pharma companies and therefore rejected early emergency authorisation. Many EU countries neither wanted nor asked for faster authorisation because of this liability issue. Pros and cons can be debated, but risk aversion in many EU countries is a fact. Anti-vaccination movements may have also added pressure on political decision-makers.

EU funding has also proven insufficient. Last year’s EU vaccine strategy allocated €2.7bn for advance purchase agreements, research and capacity. This was increased by €1.09bn in September. But these numbers are small compared with the $18bn the US provided through its “Operation Warp Speed”. Low EU purchase prices per vaccine might have further slowed down deliveries.

In recent days, there has been a debate about whether some pharma companies have breached the terms of the contracts with the EU. The EU has pre-financed the development and the production of the AstraZeneca vaccine and wants to now know exactly which doses have been produced and where, so it can assess whether contractual obligations are breached. An export transparency mechanism is being used as a threat to ensure that contractual obligations are fulfilled in case of breach of the contract. But AstraZeneca’s CEO has pointed out that the UK signed its contract three months before the EU and the UK factory also started operating earlier, increasing supply capacity. Moreover, according to AstraZeneca, its contract with the EU does not oblige early deliveries. Only publication of the contract can allow outsiders to judge this spat.

There is an argument that the EU was slow to develop an industrial strategy to increase production. The factories of competitors should have been mobilised as soon as possible to increase the total supply of vaccines. Sanofi has now agreed to use its factory in Frankfurt to produce additional BioNTech-Pfizer vaccines. The former Novartis factory in Marburg, Germany, will soon produce vaccines in large amounts. Why did governments not push earlier for more such agreements and increase financial resources to make them profitable for companies?

Last, the EU was not prepared for the pandemic. Only once it was under way did EU countries authorise the commission to start joint purchases. The US had institutions such as the Biomedical Advanced Research and Development Authority supporting research as early as February 2020. Building a racing machine only when the race has started means delays.

It is impossible to say how things would have gone if there had not been joint EU action. It seems safe to say that many EU countries would not have been able to negotiate faster vaccine deliveries with pharma companies. It also seems fair to say that the pressure from the Trump administration on pharma companies to deliver for the US market first was huge and EU countries individually would have had less leverage. Moreover, the politics of vaccine nationalism within the EU would have been toxic.

But the EU must now learn lessons. It needs institutions comparable with those of the US to deal with such situations. The commission’s initiative to boost the European Health Emergency Response Authority is to be supported. EU citizens should decide how much risk they are willing to take when it comes to vaccine authorisation and liability, and leaders should provide more financing for vaccine development and procurement. For now, the EU’s priority must be to mobilise all financial and political resources to increase vaccine supplies.

Republishing and referencing

Bruegel considers itself a public good and takes no institutional standpoint.

Due to copyright agreements we ask that you kindly email request to republish opinions that have appeared in print to [email protected].

Read about event More on this topic

Upcoming Event


How can we support and restructure firms hit by the COVID-19 crisis?

What are the vulnerabilities and risks in the enterprise sector and how prepared are countries to handle a large-scale restructuring of businesses?

Speakers: Ceyla Pazarbasioglu and Guntram B. Wolff Topic: Macroeconomic policy
Read article More on this topic More by this author



The cost of China's dynamic zero-COVID policy

What does zero-COVID mean for both China and the global economy?

By: The Sound of Economics Topic: Global economy and trade Date: May 11, 2022
Read about event More on this topic

Past Event

Past Event

From viruses to wars: recent disruptions to global trade and value chains

How have events in recent years impacted global trade and value chains and how can we strengthen these against future disruptions?

Speakers: Dalia Marin, Adil Mohommad and André Sapir Topic: Global economy and trade Date: April 27, 2022
Read article More on this topic More by this author


China’s Covid policy to be year’s largest economic shock

Beijing’s ‘dynamic zero-Covid’ policy could devastate the domestic economy, but the effects will also be felt globally.

By: Alicia García-Herrero Topic: Global economy and trade Date: April 26, 2022
Read article Download PDF More on this topic


European governance

Greening Europe’s post-COVID-19 recovery

This Blueprint includes some of the Group’s most prominent voices on the different aspects of the multidimensional issue of green recovery.

By: Simone Tagliapietra, Guntram B. Wolff, Georg Zachmann, Laurence Tubiana, Laurence Boone, Antoine Dechezleprêtre, Jean Pisani-Ferry, Klaas Lenaerts, Thomas Wieser, Ottmar Edenhofer, Mirjam Kosch, Michael Pahle, Ian Parry, Robert N. Stavins, Sabine Mauderer and Tomasz Koźluk Topic: European governance Date: February 23, 2022
Read article Download PDF More on this topic

Policy Contribution

European governance

The failure of global public health governance: a forensic analysis

The emergence of the Omicron variant in November 2021 was a stark reminder of the high overall cost of the persistence globally of extremely unequal access to vaccines and treatments. What are the reasons for these failures of global collective action?

By: Anne Bucher, George Papaconstantinou and Jean Pisani-Ferry Topic: European governance Date: February 17, 2022
Read article More on this topic

Blog Post

Venture capital: a new breath of life for European entrepreneurship?

Whether the dynamism of European venture capital of the past two years can be sustained and kick start a credible alternative to bank finance in the European Union remains to be seen.

By: Maria Demertzis and Lionel Guetta-Jeanrenaud Topic: Banking and capital markets Date: February 10, 2022
Read article Download PDF More on this topic More by this author

Policy Contribution

European governance

Does Europe need a Health Union?

This Policy Contribution assesses the rationale for a Health Union. Section 1 provides a historical perspective on health provisions in the European Union treaties. Section 2 gives an overview of the achievements of EU health policies. Section 3 explores the need for an overall health strategy and section 4 identifies the areas that would benefit from closer integration.

By: Anne Bucher Topic: European governance Date: February 8, 2022
Read article Download PDF More on this topic

Working Paper

The effect of COVID certificates on vaccine uptake, public health, and the economy

An analysis of the incentive effects of COVID certificates on vaccine uptake, health outcomes and the economy.

By: Miquel Oliu-Barton, Bary Pradelski, Nicolas Woloszko, Lionel Guetta-Jeanrenaud, Philippe Aghion, Patrick Artus, Arnaud Fontanet, Philippe Martin and Guntram B. Wolff Topic: Digital economy and innovation Date: January 17, 2022
Read article More on this topic

External Publication

Europe must come together to confront Omicron

Statement published in the renowned British Medical Journal (BMJ) to address the wave of the Omicron variant of SARS-CoV-2.

By: Miquel Oliu-Barton, Guntram B. Wolff and Group of authors Topic: Global economy and trade Date: January 13, 2022
Read article More on this topic

Blog Post

European governance

What will be the impact of Europe’s next round of COVID-19 restrictions?

As COVID-19 cases surge, the choice of restrictions, and the details of their implementation, can have a major influence on the degree to which business is impacted.

By: J. Scott Marcus and Lionel Guetta-Jeanrenaud Topic: European governance Date: December 23, 2021
Read article More by this author



Last but not the least

An overview of economic policy and beyond in 2021.

By: The Sound of Economics Topic: European governance, Global economy and trade Date: December 22, 2021
Load more posts